A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira) From North American and European Sources in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Adalimumab
- Indications Autoimmune disorders; Bone disorders; Cancer
- Focus Pharmacokinetics
- Sponsors Synermore Biologics
- 09 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.